-DOCSTART- -X- O
Hepatitis -X- _ B-Patient
B -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
HBV -X- _ I-Patient
) -X- _ I-Patient
infection -X- _ I-Patient
is -X- _ O
a -X- _ O
major -X- _ O
global -X- _ O
health -X- _ O
problem. -X- _ O
Currently-available -X- _ O
therapies -X- _ O
are -X- _ O
ineffective -X- _ O
in -X- _ O
curing -X- _ O
chronic -X- _ B-Patient
HBV -X- _ I-Patient
infection. -X- _ I-Patient
HBV -X- _ B-Patient
and -X- _ O
its -X- _ O
satellite -X- _ O
hepatitis -X- _ B-Patient
D -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
HDV -X- _ I-Patient
) -X- _ I-Patient
infect -X- _ O
hepatocytes -X- _ O
via -X- _ O
binding -X- _ O
of -X- _ O
the -X- _ O
preS1 -X- _ O
domain -X- _ O
of -X- _ O
its -X- _ O
large -X- _ O
envelope -X- _ O
protein -X- _ O
to -X- _ O
sodium -X- _ O
taurocholate -X- _ O
cotransporting -X- _ O
polypeptide -X- _ O
( -X- _ O
NTCP -X- _ O
) -X- _ O
. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
developed -X- _ O
novel -X- _ B-Intervention
human -X- _ I-Intervention
monoclonal -X- _ I-Intervention
antibodies -X- _ I-Intervention
that -X- _ O
block -X- _ O
the -X- _ O
engagement -X- _ O
of -X- _ O
preS1 -X- _ O
with -X- _ O
NTCP -X- _ O
and -X- _ O
neutralize -X- _ O
HBV -X- _ B-Patient
and -X- _ I-Patient
HDV -X- _ I-Patient
with -X- _ O
high -X- _ O
potency. -X- _ O
One -X- _ B-Outcome
antibody -X- _ I-Outcome
, -X- _ I-Outcome
2H5-A14 -X- _ I-Outcome
, -X- _ I-Outcome
functions -X- _ I-Outcome
at -X- _ I-Outcome
picomolar -X- _ I-Outcome
level -X- _ I-Outcome
and -X- _ I-Outcome
exhibited -X- _ I-Outcome
neutralization-activity-mediated -X- _ I-Outcome
prophylactic -X- _ I-Outcome
effects. -X- _ I-Outcome
It -X- _ I-Outcome
also -X- _ I-Outcome
acts -X- _ I-Outcome
therapeutically -X- _ I-Outcome
by -X- _ I-Outcome
eliciting -X- _ I-Outcome
antibody-Fc-dependent -X- _ I-Outcome
immunological -X- _ I-Outcome
effector -X- _ I-Outcome
functions -X- _ I-Outcome
that -X- _ I-Outcome
impose -X- _ I-Outcome
durable -X- _ I-Outcome
suppression -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
infection -X- _ I-Outcome
in -X- _ I-Outcome
HBV-infected -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
resulting -X- _ I-Outcome
in -X- _ I-Outcome
reductions -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
small -X- _ I-Outcome
envelope -X- _ I-Outcome
antigen -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
DNA -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
no -X- _ I-Outcome
emergence -X- _ I-Outcome
of -X- _ I-Outcome
escape -X- _ I-Outcome
mutants. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
illustrate -X- _ O
a -X- _ O
novel -X- _ B-Outcome
antibody-Fc-dependent -X- _ I-Outcome
approach -X- _ I-Outcome
for -X- _ I-Outcome
HBV -X- _ I-Outcome
treatment -X- _ I-Outcome
and -X- _ I-Outcome
suggest -X- _ I-Outcome
2H5-A14 -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
novel -X- _ I-Outcome
clinical -X- _ I-Outcome
candidate -X- _ I-Outcome
for -X- _ I-Outcome
HBV -X- _ I-Outcome
prevention -X- _ I-Outcome
and -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
chronic -X- _ I-Outcome
HBV -X- _ I-Outcome
infection -X- _ I-Outcome
. -X- _ O

